Overview
- Donevan, S.D. et al. (1998) J. Pharmacol. Exp. Ther. 285, 539.
- Traynelis, S.F. et al. (2010) Pharmacol. Rev. 62, 405.
- Armstrong, N. and Gouaux, E. (2000) Neuron 28, 165.
- Kim, S. et al. (2017) Exp. Neurobiol. 26, 266.
- Foster, J.A. et al. (2003) J. Chem. Neuroanat. 26, 65.
Alomone Labs Kainic acid monohydrate activates kainate receptors expressed in Xenopus oocytes.A representative time course of GluK1 (GluR5) current, activated by a transient application of 1 µM Kainic acid monohydrate (#K-200) at a holding potential of -80 mV.
- Kim, S. et al. (2017) Exp. Neurobiol. 26, 266.
- Wang, Y. et al. (2008) Autophagy 4, 214.
- Foster, J.A. et al. (2003) J. Chem. Neuroanat. 26, 65.
- Orav, E. et al. (2017) eNeuro 4, e0048.
Kainic acid is an analog of the excitotoxic neurotransmitter glutamate used as a selective agonist of Kainate receptors1,2.
Studies show that treatment with Kainic acid may induce seizures leading to neuronal death and biochemical changes similar to those seen in human patients with temporal lobe epilepsy1. Kainic acid may induce apoptotic death of rat striatal neurons in an autophagic mechanism2. Several studies of rat model show progressive death of nigral neurons following unilateral injection of Kainic acid in the striatum3.
Kainate-type glutamate receptors (KARs) are highly expressed in the developing brain, where they are tonically activated to modulate synaptic transmission, network excitability and synaptogenesis4.
Kainic acid monohydrate (#K-200) is a highly pure, synthetic, and biologically active compound.
Powered by Bioz
